Giles W. Robinson
Memphis paediatric neuro-oncologist who led the study showing that the Hedgehog inhibitor vismodegib helps only adults and older children whose medulloblastoma belongs to the SHH subgroup, an early example of subgroup-directed brain tumour therapy.
Overview
Giles Robinson is a paediatric neuro-oncologist at St. Jude Children's Research Hospital and leads its medulloblastoma programme, including the SJMB12 trial that treats patients according to molecular subgroup. He was first author of the 2015 Journal of Clinical Oncology report of the vismodegib trials in recurrent medulloblastoma, which showed responses were confined to SHH-subgroup tumours with upstream pathway mutations and that the drug caused growth-plate fusion in growing children.
Similar pages
not linked directly; found by shared links- PersonDarren R. Hargrave
Shares Childhood cancers (all types) and the tags paediatric, brain, targeted-therapy, trialist.
- PersonSarah E. S. Leary
Shares Childhood cancers (all types), Medulloblastoma and the tags paediatric, brain, trialist.
- PersonJacques Grill
Shares Childhood cancers (all types) and the tags paediatric, brain, trialist.
- PersonAmar Gajjar
Shares St. Jude Children's Research Hospital, Medulloblastoma and the tag paediatric.
- PersonRob Pieters
Shares Childhood cancers (all types) and the tags paediatric, trialist.
- PersonKimberly P. Dunsmore
Shares Childhood cancers (all types) and the tags paediatric, trialist.
- PersonAndrew B. Lassman
Shares the tags brain, trialist.
- PersonJan C. Buckner
Shares the tags brain, trialist.